1. Scrip
  2. >>Business

AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer

Too Little, Too Late In Crowded Market

 
• By Andrew McConaghie

The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.

Astrazeneca
AstraZeneca is the market leader in EGFR-positive lung cancer, but trails far behind Merck and BMS in the PD-1/PD-L1 market.

AstraZeneca’s Imfinzi and tremelimumab combination with chemotherapy has achieved success in extending lives in first-line non-small cell lung cancer (NSCLC) patients, but has failed to match the performance of rival leading immunotherapies.

The Phase III POSEIDON results are a long-awaited victory after a string of failures for the combination, but will not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Lilly CEO Ricks Advocates Rebalancing Drug Pricing Between US And Europe

 
• By Mandy Jackson

As President Trump focuses on “most favored nation” pricing to bring down US drug costs, CEO David Ricks used Lilly’s Q2 earnings call to advocate for a slow approach to reducing the difference between US and EU drug prices.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

Sanofi’s Sarclisa Wins Another EU Multiple Myeloma Nod In Its Unequal Battle With J&J’s Darzalex

 
• By Sushmita Panda

The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.